Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma

Research output: Contribution to journalLetter

Details

Authors
Organisations
External organisations
  • Copenhagen University Hospital
  • Skåne University Hospital
  • Oslo university hospital
  • Uppsala University Hospital
  • Helsinki University Central Hospital
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Cancer and Oncology
Original languageEnglish
Pages (from-to)e541-e543
JournalHaematologica
Volume103
Issue number11
Publication statusPublished - 2018
Publication categoryResearch
Peer-reviewedYes